-
Je něco špatně v tomto záznamu ?
Interplay of drug transporters P-glycoprotein (MDR1), MRP1, OATP1A2 and OATP1B3 in passage of maraviroc across human placenta
L. Tupova, B. Hirschmugl, S. Sucha, V. Pilarova, V. Székely, É. Bakos, L. Novakova, C. Özvegy-Laczka, C. Wadsack, M. Ceckova
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
Elsevier Open Access Journals od 2018-12-01
ROAD: Directory of Open Access Scholarly Resources od 2002
Odkazy
PubMed
32768979
DOI
10.1016/j.biopha.2020.110506
Knihovny.cz E-zdroje
- MeSH
- akridiny farmakologie MeSH
- buňky MDCK MeSH
- látky proti HIV krev metabolismus farmakologie MeSH
- lékové interakce MeSH
- lidé MeSH
- maravirok krev metabolismus MeSH
- nádorové buněčné linie MeSH
- P-glykoproteiny antagonisté a inhibitory genetika metabolismus MeSH
- perfuze MeSH
- placenta účinky léků metabolismus MeSH
- placentární oběh MeSH
- přenašeče organických aniontů antagonisté a inhibitory genetika metabolismus MeSH
- protein OATP1B3 antagonisté a inhibitory genetika metabolismus MeSH
- proteiny spojené s mnohočetnou rezistencí k lékům genetika metabolismus MeSH
- psi MeSH
- regulace genové exprese MeSH
- ritonavir farmakologie MeSH
- těhotenství MeSH
- tetrahydroisochinoliny farmakologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- psi MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Special attention is required when pharmacological treatment is indicated for a pregnant woman. P-glycoprotein (MDR1) is a well-known transporter localized in the maternal blood-facing apical membrane of placental syncytiotrophoblast and is considered to play an important role in protecting the developing fetus. Maraviroc, a MDR1 substrate that is registered for treatment of HIV infection, shows a low toxicity profile, suggesting favorable tolerability also if administered to pregnant women. Nevertheless, there is only poor understanding to date regarding the extent to which it permeates across the placental barrier and what are the transport mechanisms involved. Endeavoring to clarify the passage of maraviroc across placenta, we used in this study the method of closed-circuit perfusion of maraviroc across human placental cotyledon. The data obtained confirmed slight involvement of MDR1, but they also suggest possible interaction with other transport system(s) working in the opposite direction from that of MDR1. Complementary in vitro studies, including cellular experiments on choriocarcinoma BeWo cells as well as transporter-overexpressing MDCKII and A431 cell lines and accumulation in placental fresh villous fragments, revealed maraviroc transport by MRP1, OATP1A2, and OATP1B3 transporters. Based on mRNA expression data in the placental tissue, isolated trophoblasts, and fetal endothelial cells, especially MRP1 and OATP1A2 seem to play a crucial role in cooperatively driving maraviroc into placental tissue. By the example of maraviroc, we show here the important interplay of transporters in placental drug handling and its possibility to overcome the MDR1-mediated efflux.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012175
- 003
- CZ-PrNML
- 005
- 20210507101629.0
- 007
- ta
- 008
- 210420s2020 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2020.110506 $2 doi
- 035 __
- $a (PubMed)32768979
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Tupova, Lenka $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic
- 245 10
- $a Interplay of drug transporters P-glycoprotein (MDR1), MRP1, OATP1A2 and OATP1B3 in passage of maraviroc across human placenta / $c L. Tupova, B. Hirschmugl, S. Sucha, V. Pilarova, V. Székely, É. Bakos, L. Novakova, C. Özvegy-Laczka, C. Wadsack, M. Ceckova
- 520 9_
- $a Special attention is required when pharmacological treatment is indicated for a pregnant woman. P-glycoprotein (MDR1) is a well-known transporter localized in the maternal blood-facing apical membrane of placental syncytiotrophoblast and is considered to play an important role in protecting the developing fetus. Maraviroc, a MDR1 substrate that is registered for treatment of HIV infection, shows a low toxicity profile, suggesting favorable tolerability also if administered to pregnant women. Nevertheless, there is only poor understanding to date regarding the extent to which it permeates across the placental barrier and what are the transport mechanisms involved. Endeavoring to clarify the passage of maraviroc across placenta, we used in this study the method of closed-circuit perfusion of maraviroc across human placental cotyledon. The data obtained confirmed slight involvement of MDR1, but they also suggest possible interaction with other transport system(s) working in the opposite direction from that of MDR1. Complementary in vitro studies, including cellular experiments on choriocarcinoma BeWo cells as well as transporter-overexpressing MDCKII and A431 cell lines and accumulation in placental fresh villous fragments, revealed maraviroc transport by MRP1, OATP1A2, and OATP1B3 transporters. Based on mRNA expression data in the placental tissue, isolated trophoblasts, and fetal endothelial cells, especially MRP1 and OATP1A2 seem to play a crucial role in cooperatively driving maraviroc into placental tissue. By the example of maraviroc, we show here the important interplay of transporters in placental drug handling and its possibility to overcome the MDR1-mediated efflux.
- 650 _2
- $a P-glykoproteiny $x antagonisté a inhibitory $x genetika $x metabolismus $7 D018435
- 650 _2
- $a akridiny $x farmakologie $7 D000166
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a látky proti HIV $x krev $x metabolismus $x farmakologie $7 D019380
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a psi $7 D004285
- 650 _2
- $a lékové interakce $7 D004347
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese $7 D005786
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a buňky MDCK $7 D061985
- 650 _2
- $a maravirok $x krev $x metabolismus $7 D000077592
- 650 _2
- $a proteiny spojené s mnohočetnou rezistencí k lékům $x genetika $x metabolismus $7 D027425
- 650 _2
- $a přenašeče organických aniontů $x antagonisté a inhibitory $x genetika $x metabolismus $7 D027361
- 650 _2
- $a perfuze $7 D010477
- 650 _2
- $a placenta $x účinky léků $x metabolismus $7 D010920
- 650 _2
- $a placentární oběh $7 D021041
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a ritonavir $x farmakologie $7 D019438
- 650 _2
- $a protein OATP1B3 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D000074542
- 650 _2
- $a tetrahydroisochinoliny $x farmakologie $7 D044005
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hirschmugl, Birgit $u Medical University of Graz, Department of Obstetrics and Gynecology, 8036, Graz, Austria
- 700 1_
- $a Sucha, Simona $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic
- 700 1_
- $a Pilarova, Veronika $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Analytical Chemistry, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic
- 700 1_
- $a Székely, Virág $u Membrane Protein Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Magyar tudósok krt. 2., H-1117, Budapest, Hungary
- 700 1_
- $a Bakos, Éva $u Membrane Protein Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Magyar tudósok krt. 2., H-1117, Budapest, Hungary
- 700 1_
- $a Novakova, Lucie $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Analytical Chemistry, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic
- 700 1_
- $a Özvegy-Laczka, Csilla $u Membrane Protein Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Magyar tudósok krt. 2., H-1117, Budapest, Hungary
- 700 1_
- $a Wadsack, Christian $u Medical University of Graz, Department of Obstetrics and Gynecology, 8036, Graz, Austria
- 700 1_
- $a Ceckova, Martina $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic. Electronic address: martina.ceckova@faf.cuni.cz
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 129, č. - (2020), s. 110506
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32768979 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507101629 $b ABA008
- 999 __
- $a ok $b bmc $g 1650531 $s 1132554
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 129 $c - $d 110506 $e 20200712 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
- LZP __
- $a Pubmed-20210420